PURPOSE: The thymidine analog 3'-deoxy-3'-[(18)F]fluorothymidine ((18)F-FLT) has been developed as a positron emission tomography (PET) tracer to assess the proliferation activity of tumors in vivo. The present study investigated the relationship between the kinetic parameters of (18)F-FLT in vivo and thymidine kinase-1 (TK-1) expression and cell proliferation rate in vitro, and blood-brain barrier (BBB) breakdown in human brain gliomas. METHODS: A total of 21 patients with newly diagnosed gliomas were examined by (18)F-FLT PET kinetic analysis. Maximum standardized uptake value (SUVmax) and tumor-to-normal (T/N) ratio of (18)F-FLT in the tumor and (18)F-FLT kinetic parameters in the corresponding contralateral region were determined. The expression levels of TK-1 protein and mRNA were determined by immunohistochemistry (IHC) and real-time polymerase chain reaction (PCR), respectively, using surgical specimens. The cell proliferation rate of the tumor was determined in terms of the Ki-67 labeling index. BBB breakdown was evaluated on MR images with contrast enhancement. RESULTS: (18)F-FLT SUVmax and T/N ratio were significantly correlated with the influx rate constant (K (1); P = 0.001 and P < 0.001, respectively), but not with the phosphorylation rate constant (k (3)). IHC and real-time PCR studies demonstrated a significant correlation between K (1) and TK-1 mRNA expression (P = 0.001), but not between k (3) and TK-1 protein and mRNA expression. Linear regression analysis revealed a significant correlation between K (1) and the Ki-67 index (P = 0.003), but not between k (3) and the Ki-67 index. TK-1 mRNA expression was significantly correlated with the Ki-67 index (P = 0.009). (18)F-FLT SUVmax and T/N ratio were significantly correlated with BBB breakdown evaluated by contrast enhancement in MR images (P = 0.003 and P = 0.011, respectively). CONCLUSION: These results indicate that (18)F-FLT uptake in the tumor is significantly related to transport through the disrupted BBB, but not through phosphorylation activity. Although the tissue TK-1 expression reflects tumor proliferation activity, the phosphorylation rate constant k (3) determined by (18)F-FLT PET kinetic analysis does not accurately reflect TK-1 expression in the tissue and should not be used as a surrogate biomarker of cell proliferation activity in human brain gliomas.
PURPOSE: The thymidine analog 3'-deoxy-3'-[(18)F]fluorothymidine ((18)F-FLT) has been developed as a positron emission tomography (PET) tracer to assess the proliferation activity of tumors in vivo. The present study investigated the relationship between the kinetic parameters of (18)F-FLT in vivo and thymidine kinase-1 (TK-1) expression and cell proliferation rate in vitro, and blood-brain barrier (BBB) breakdown in humanbrain gliomas. METHODS: A total of 21 patients with newly diagnosed gliomas were examined by (18)F-FLT PET kinetic analysis. Maximum standardized uptake value (SUVmax) and tumor-to-normal (T/N) ratio of (18)F-FLT in the tumor and (18)F-FLT kinetic parameters in the corresponding contralateral region were determined. The expression levels of TK-1 protein and mRNA were determined by immunohistochemistry (IHC) and real-time polymerase chain reaction (PCR), respectively, using surgical specimens. The cell proliferation rate of the tumor was determined in terms of the Ki-67 labeling index. BBB breakdown was evaluated on MR images with contrast enhancement. RESULTS: (18)F-FLT SUVmax and T/N ratio were significantly correlated with the influx rate constant (K (1); P = 0.001 and P < 0.001, respectively), but not with the phosphorylation rate constant (k (3)). IHC and real-time PCR studies demonstrated a significant correlation between K (1) and TK-1 mRNA expression (P = 0.001), but not between k (3) and TK-1 protein and mRNA expression. Linear regression analysis revealed a significant correlation between K (1) and the Ki-67 index (P = 0.003), but not between k (3) and the Ki-67 index. TK-1 mRNA expression was significantly correlated with the Ki-67 index (P = 0.009). (18)F-FLT SUVmax and T/N ratio were significantly correlated with BBB breakdown evaluated by contrast enhancement in MR images (P = 0.003 and P = 0.011, respectively). CONCLUSION: These results indicate that (18)F-FLT uptake in the tumor is significantly related to transport through the disrupted BBB, but not through phosphorylation activity. Although the tissue TK-1 expression reflects tumor proliferation activity, the phosphorylation rate constant k (3) determined by (18)F-FLT PET kinetic analysis does not accurately reflect TK-1 expression in the tissue and should not be used as a surrogate biomarker of cell proliferation activity in humanbrain gliomas.
Authors: Yuka Yamamoto; Terence Z Wong; Timothy G Turkington; Thomas C Hawk; David A Reardon; R Edward Coleman Journal: Mol Imaging Biol Date: 2006 Nov-Dec Impact factor: 3.488
Authors: J Scott Brockenbrough; Timothee Souquet; Janice K Morihara; Joshua E Stern; Stephen E Hawes; Janet S Rasey; Antoine Leblond; Linda W Wiens; Qinghua Feng; John Grierson; Hubert Vesselle Journal: J Nucl Med Date: 2011-07-15 Impact factor: 10.057
Authors: Ulrike Seitz; Martin Wagner; Bernd Neumaier; Edgar Wawra; Gerhard Glatting; Gerhard Leder; Roland M Schmid; Sven N Reske Journal: Eur J Nucl Med Mol Imaging Date: 2002-06-04 Impact factor: 9.236
Authors: Henryk Barthel; Meg Perumal; John Latigo; Qimin He; Frank Brady; Sajinder K Luthra; Pat M Price; Eric O Aboagye Journal: Eur J Nucl Med Mol Imaging Date: 2004-09-04 Impact factor: 9.236
Authors: Randy Yeh; Megan H Trager; Emanuelle M Rizk; Grace G Finkel; Luke W Barker; Richard D Carvajal; Larisa J Geskin; Gary K Schwartz; Lawrence Schwartz; Laurent Dercle; Yvonne M Saenger Journal: Clin Nucl Med Date: 2020-04 Impact factor: 7.794
Authors: Laura L Boles Ponto; Susan Walsh; Jiangeng Huang; Christine Mundt; Katherine Thede-Reynolds; G Leonard Watkins; John Sunderland; Michael Acevedo; Maureen Donovan Journal: AAPS J Date: 2017-12-07 Impact factor: 4.009
Authors: Nancy U Lin; Laleh Amiri-Kordestani; Diane Palmieri; David J Liewehr; Patricia S Steeg Journal: Clin Cancer Res Date: 2013-12-01 Impact factor: 12.531
Authors: Martin A Lodge; Matthias Holdhoff; Jeffrey P Leal; Asim K Bag; L Burt Nabors; Akiva Mintz; Glenn J Lesser; David A Mankoff; Arati S Desai; James M Mountz; Frank S Lieberman; Joy D Fisher; Serena Desideri; Xiaobu Ye; Stuart A Grossman; David Schiff; Richard L Wahl Journal: J Nucl Med Date: 2016-09-29 Impact factor: 10.057
Authors: Martha Nowosielski; Matthew D DiFranco; Daniel Putzer; Marcel Seiz; Wolfgang Recheis; Andreas H Jacobs; Günther Stockhammer; Markus Hutterer Journal: PLoS One Date: 2014-04-23 Impact factor: 3.240